In the 2025 MOASC Breast Cancer Updates, Evanthia Roussos Torres, MD, delivers a compelling overview of the current challenges and…
Browsing: Breast
Breast Cancer
FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Breast Cancer: A New Milestone in TreatmentPublished: February 20, 2025On January 27,…
Date: February 8, 2025The U.S. Food and Drug Administration (FDA) has recently granted approval for datopotamab deruxtecan (DLNK), a new…
Dive into the groundbreaking results of the EMBER-3 Phase 3 trial (NCT04975308) as presented by Dr. Virginia Kaklamani from UT…
BRCA Carriers Slicing Breast Cancer Odds: Does Surgery Really Lead to Longevity Leaps? Text: @OncoAlert @oncology @BreastCancerNow @SABCS @ProfMatteoLambertini #SABCS24…
Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results Text Version: @DFCI_BreastOnc @Otto_DFCI @OncoAlert @PfizerIbrance @pfizer_news @SABCSSanAntonio @AACR #SABCS24…
We recognize that That combination also made them immunogenic. And so there was always recognition. Over time we came to appreciate that when you see the immune system in there where there’s immune lymphocytes in the tumor, those tumors, those patients seem to do better even in the absence of drug therapy and with drug therapy they do better still.
“So basically, we looked at two factors, the one saying the long term remission of heart positive metastatic breast cancer…
In his analysis, Paolo Tarantino, MD, delves into the transformative potential of CDK4/6 inhibitors in breast cancer therapy. He questions whether these drugs, celebrated for their promise in clinical trials, have truly matched expectations in real-world scenarios, specifically referencing data from the NATALEE and monarchE trials. The discussion is visually represented by a superhero figure donning a CDK4/6 emblem, symbolizing the hope and power these inhibitors bring to the fight against breast cancer. This image captures the essence of current medical debates surrounding the efficacy and application of these treatments in managing breast cancer recurrence and overall patient outcomes.
The ZEST trial marks a pivotal moment in oncology, focusing on circulating tumor DNA (ctDNA) surveillance to detect molecular residual disease in breast cancer patients. This study explored whether Niraparib, a PARP inhibitor, could extend disease-free survival in patients with detectable ctDNA post-treatment but without visible signs of recurrence. The findings offer insights into both the potential and the limitations of using ctDNA for personalized cancer management.
The San Antonio Breast Cancer Symposium (SABCS) 2024 showcased new data from the DESTINY-Breast06 study, examining the efficacy of ENHERTU®…
EMBER-3 Trial: Pioneering Results in Advanced Breast Cancer TreatmentThe results of the Phase 3 EMBER-3 trial were unveiled at the…
The FDA has recently approved Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (NSAI) for the treatment of early-stage…
Dr. Nathalie M. Johnson, MD, a breast cancer specialist with Legacy Health Partners, delves into the evolving role of circulating…
IntroductionDr. Kevin Hughes, MD, from MUSC Health, sheds light on a critical issue in the field of oncology: the underutilization…
Genetic Testing CancerIn recent years, the field of oncology has witnessed significant advancements, particularly in the realm of genetic testing.…
In the evolving landscape of cancer treatment, ctDNA (circulating tumor DNA) testing has emerged as a pivotal tool in managing…
Author: Dr. Alexis LeVee, City of HopeAt the ASCO 2024 conference, Dr. Alexis LeVee from City of Hope presented a…
IntroductionThe recent findings from the DESTINY-Breast06 Phase III trial signify a potential shift in the treatment landscape for HR-positive, HER2-low…
…[VIDEO with 39 SLIDES] – Dr. Rebecca Shatsky, MD from the 2024 MOASC Annual Oncology Summit & Research SymposiumIn the…
Wassim Mchayleh, MD, a speaker at the Medical Data and Analysis Symposium (MDAS), discusses the integration of circulating tumor DNA…
By. Halle Moore, MD Date. 12/13/2023 Halle Moore, MD, the Medical Doctor and Director of Breast Medical Oncology and Co-Director…
Amidst the atmosphere of SABCS 2023, and at the center was Yara Abdou, MD, a medical oncologist from the University…
Allen Wilbanks stands at the forefront of SABCS 2023, the setting for a conversation with Thomas Budd, MD, a medical…
Allen Wilbanks finds himself at SABCS 2023, where he engages in a discussion with Dr. Adam Brufsky, a medical doctor,…
Wassim Mchayleh, MD, an expert in oncology, participated in the SABCS 2023 conference, offering insights into the latest developments in…
Allen Wilbanks stood alongside Alina Hamilton, PhD, at the SABCS 2023 event, where they delved into groundbreaking research on breast…
By: Melinda Telli, MD, Date: 12/9/2023 At the SABCS 2023 conference, we had the privilege of interviewing Melinda Telli, MD,…
By: Hope Rugo, MD Date: 12/9/2023 At the SABCS 2023 conference, medical oncologist Hope Rugo from the University of California,…
By: Yara Abdou, MD, Date. 12/08/2023 At SABCS 2023, Yara Abdou, MD, a medical oncologist from the University of North…
By: Hatem Azim, MD Date. 12/08/2023At SABCS 2023, a discussion on fertility preservation and assisted reproductive technologies in breast cancer patients…
Treatment differences by race and age in metastatic hormone receptor-positive/HER2- with Yara Abdour, MDTranscript (spelling not corrected)Yara Abdou, MD -…
By: Julie Lang, MD Date. 12/07/2023Julie Lang, MD, a medical professional known for expertise in breast cancer research, has developed…
By. Terry Mamounas Date: 12/07/2023In a collaborative study between NVP and RT, led by oncologist Terry Mamounas, MD, the NSABP…
By. Kellogg Parsons, MD Date: 12/07/2023 Kellogg Parsons, MD, a medical doctor and Vice President of Clinical Development at Embrace Therapeutics,…
By. Ruth O’Regan MD Date: 12/07/2023In an interview, Ruth O’Regan MD addresses questions related to the use of CDK4/6 inhibitors in…
By. Neil Carleton, MD Date. 12/07/2023 In the interview with Neil Carleton, MD, the discussion revolved around the age-related remodeling of…
By: Carol Fabian, MD Date. 12/07/2023 In an interview, Carol Fabian, MD, an expert in breast cancer research and prevention, will…
By: Joyti Bajpai, MD Date: 12/07/2023 In a forthcoming interview, Jyoti Bajpai, MD, a renowned expert in the field, will…
By. Peter Schmid, FRCP, MD, PhD Date. 10/11/2023 KEYNOTE-522 Phase 3 Results – Was Pembrolizumab a Win in Triple-Negative Breast…
By. Stuart McIntosh, MDDate. November 03, 2023Stuart McIntosh, MD, Chief Medical Officer, initiated a study in the field of oncology.…
By. Aditya Bardia, MDDate. November 01, 2023 Dr. Aditya Bardia, an oncologist specializing in breast cancer treatment, provided insights into…
In a recent interview, Peter Fasching, MD, Professor of Women’s Cancer Specialist at the University Hospital in Erlangen, Germany, discussed…
Sayeh Lavasani, MD of UCI Health gives an Update in Breast Cancer at MOASC’s Spotlight on Oncology NATALEE’s study focused…
Dr. Sayeh Lavasani, MD, MSc, FRCPC, an Associate Clinical Professor in the Division of Hematology Oncology at the Department of…
Breast cancer is a topic that has garnered significant attention over the years, and for good reason. Affecting millions worldwide,…
Virginia Kaklamani, MD – UT Health San Antonio discusses Elacestrant (ORSERDU), an oral endocrine therapy, has been approved by the…
KEY TAKEAWAYS: Ribociclib, a CDK4/6 inhibitor, is a promising drug in the treatment of early-stage and metastatic breast cancer, particularly…
TROPiCS-02 Trial: The TROPiCS-02 trial showcases the potential of Sacituzumab Govitecan, a Trop-2 directed antibody-drug conjugate, as a promising treatment…
Abemaciclib, a CDK4 & 6 inhibitor, has shown a sustained benefit in invasive disease-free survival in high-risk EBC, as seen…
Constantinos Savva, MD, M.Sc., PGDip, MRCP, SCE, from the University of Southampton conducted a study on the effects of metformin,…
Erika Hamilton, MD, a preeminent expert from the Sarah Cannon Research Institute, has recently conducted a study evaluating the efficacy…
Nadia Harbeck, MD, PhD, from the University of Münster, recently conducted a primary outcome analysis of the multicenter randomized PreCycle…
Ian Krop, MD, PhD – Yale University This study conducted an age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients…
Sara Tolaney, MD, a renowned researcher from the Dana-Farber Cancer Institute, has recently conducted a groundbreaking study that has been…
Adam Brufsky, MD, PhD from the University of Pittsburgh discussed the higher risk of recurrence in certain breast cancer patients…
Introduction to Locally Advanced Breast Cancer Breast cancer is one of the most common types of cancer diagnosed in women…
by Hope Rugo, MD – UCSF Dr. Hope S. Rugo is a highly respected oncologist and professor of medicine specializing…
Dr. Javier Cortes discussed the PHERGain clinical study is a phase 2 trial focused on the potential deescalation of chemotherapy…
The medical field is abuzz with the exciting announcement of Novartis reporting positive topline results for the NATALEE trial (Phase…
Breast Cancer Treatment: How is Biology’s Integration into the Clinic Transforming Healthcare? Hope Rugo By Hope Rugo, MD, FASCO, Professor,…
HER2 Low Breast Cancer: What Are the Latest Advancements in Novel Drug Antibody Conjugates for 2023? Yuan Yuan MD By…
Insights on Breast Cancer Treatment: Yuan Yuan, MD’s Discussion on Sacituzumab Govitecan and Other Novel Treatments By Yuan Yuan, MD,…
Leptomeningeal Disease: Phase 1 Trial of BBB-Penetrant HER2 Inhibitor in Metastatic Breast Cancer Nicholas McAndrew MD By Nicholas McAndrew, MD,…
Polygenic Risk Score: Validation of a Breast Cancer Risk Prediction Model in a Large Prospective Cohort Thomas Slavin, MD By…
Endocrine Therapy: 70-Gene MammaPrint Test Predicts Benefit in Early-Stage Breast Cancer Laura Van ’t Veer By Laura Van ‘t Veer,…
NanoString: Intrinsic Subtypes and 21-Gene Assay Predict Recurrence in Early Stage HER2+ Breast Cancer from Saranya Chumsri MD By Saranya…
Breast Cancer Index: Prospective Evaluation Insights from Kai Treuner PhD By Kai Treuner, PhD So the breast cancer index is…
PACE Trial: Palbociclib, Fulvestrant, and Avelumab in Endocrine Pre-treated Metastatic Breast Cancer Erica Mayer MD By Erica Mayer, MD So…
Polygenic Risk Score: Validation of a Breast Cancer Risk Prediction Model in a Large Prospective Cohort Thomas Slavin, MD By…
Endocrine Therapy: 70-Gene MammaPrint Test Predicts Benefit in Early-Stage Breast Cancer Laura Van ’t Veer By Laura Van ‘t Veer,…
NanoString: Intrinsic Subtypes and 21-Gene Assay Predict Recurrence in Early Stage HER2+ Breast Cancer from Saranya Chumsri MD By Saranya…
Breast Cancer Index: Prospective Evaluation Insights from Kai Treuner PhD By Kai Treuner, PhD So the breast cancer index is…
PACE Trial: Palbociclib, Fulvestrant, and Avelumab in Endocrine Pre-treated Metastatic Breast Cancer Erica Mayer MD By Erica Mayer, MD So…
Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellisen MD By Leif Ellisen, MD So…
Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022 By Steffi Oesterreich, PhD So,…
Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD By Saranya Chumsri, MD…
iFrame is not supported! Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellisen MD By…
iFrame is not supported! Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022 By…
iFrame is not supported! Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD…
Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD By Nora Disis, MD…
Antibody-Drug Conjugate Advancements for Breast Cancer Treatment: Updates from SABCS 2022 by Leif Ellisen MD By Leif Ellisen, MD So…
Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022 By Steffi Oesterreich, PhD So,…
Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD By Saranya Chumsri, MD…
The Significance of ctDNA in Predicting Recurrence and Delaying Progression in Breast Cancer Patients Mridula George MD By Mridula George,…
iFrame is not supported! Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD…
The Importance of ctDNA in Breast Cancer Diagnosis and Treatment Planning Mridula George MD By Mridula George, MD Breast cancer…
iFrame is not supported! The Significance of ctDNA in Predicting Recurrence and Delaying Progression in Breast Cancer Patients Mridula George…
Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD By Nora Disis, MD…
iFrame is not supported! The Importance of ctDNA in Breast Cancer Diagnosis and Treatment Planning Mridula George MD By Mridula…
The Significance of ctDNA in Predicting Recurrence and Delaying Progression in Breast Cancer Patients Mridula George MD By Mridula George,…
The Importance of ctDNA in Breast Cancer Diagnosis and Treatment Planning Mridula George MD By Mridula George, MD Breast cancer…
Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So after a patient’s cancer…
iFrame is not supported! Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So…
FLEX Trial Breast Cancer: SABCS 2022 Mehran Habnibi MD Looking at Gene Mutations By Mehran Habibi, MD, MBA The new…
iFrame is not supported! FLEX Trial Breast Cancer: SABCS 2022 Mehran Habnibi MD Looking at Gene Mutations By Mehran Habibi,…
Elacestrant: FDA Grants Approval for Breast Cancer Treatment: Insights from Virginia Kaklamani By Virginia Kaklamani So after a patient’s cancer…
FLEX Trial Breast Cancer: SABCS 2022 Mehran Habnibi MD Looking at Gene Mutations By Mehran Habibi, MD, MBA The new…
Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the patient-reported outcomes from the…
iFrame is not supported! Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the…
Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the patient-reported outcomes from the…
Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics By Professor Adrian Lee How can heterogeneity in breast cancer…
iFrame is not supported! Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics By Professor Adrian Lee How can…
Heterogeneity: SABCS 2022 Adrian Lee PhD Highlighted Research in Transcriptomics By Professor Adrian Lee How can heterogeneity in breast cancer…
PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients suffering with breast…
iFrame is not supported! PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients…
PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients suffering with breast…
Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with…
iFrame is not supported! Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results…
Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with…
ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor degrader do for patients…
iFrame is not supported! ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor…
ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor degrader do for patients…
For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…
For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…
For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…
For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…
For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…
For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…
Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present study of Adolescent and Young…
Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present study of Adolescent and Young…
iFrame is not supported! Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present…
DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan versus trastuzumab emtansine reveal for…
iFrame is not supported! DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan…
DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan versus trastuzumab emtansine reveal for…
IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is IHC 0 in HER2…
iFrame is not supported! IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is…
IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is IHC 0 in HER2…
RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety and fatigue in women,…
iFrame is not supported! RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety…
RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety and fatigue in women,…
Endocrine Therapy: SABCS 2022 Halle Moore POSITIVE Trial Breast Cancer How does endocrine therapy (aromatase inhibitor) effect women with endocrine…
iFrame is not supported! Endocrine Therapy: SABCS 2022 Halle Moore POSITIVE Trial Breast Cancer How does endocrine therapy (aromatase…
Endocrine Therapy: SABCS 2022 Halle Moore POSITIVE Trial Breast Cancer How does endocrine therapy (aromatase inhibitor) effect women with endocrine…
FGFR2: Breast Cancer Suneel Kamath SABCS 2022 ReFocus Trial How can FGFR2 inhibitors like RLY-4008 help with patients suffering…
iFrame is not supported! FGFR2: Breast Cancer Suneel Kamath SABCS 2022 ReFocus Trial How can FGFR2 inhibitors like RLY-4008…
FGFR2: Breast Cancer Suneel Kamath SABCS 2022 ReFocus Trial How can FGFR2 inhibitors like RLY-4008 help with patients suffering…
Bisphosphonates: Breast Cancer Julia Foldi SABCS 2022 Cohort Study How can BMAs (zoledronic acid) help oncology patients with early-stage…
iFrame is not supported! Bisphosphonates: Breast Cancer Julia Foldi SABCS 2022 Cohort Study How can BMAs (zoledronic acid) help…
Bisphosphonates: Breast Cancer Julia Foldi SABCS 2022 Cohort Study How can BMAs (zoledronic acid) help oncology patients with early-stage…
Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab help patients with TMAs?…
MammaPrint: Breast Cancer Dr. Nasrazadani SABCS 2022 70-gene 10 Year Follow Up What has this 10 year follow up…
iFrame is not supported! MammaPrint: Breast Cancer Dr. Nasrazadani SABCS 2022 70-gene 10 Year Follow Up What has this…
MammaPrint: Breast Cancer Dr. Nasrazadani SABCS 2022 70-gene 10 Year Follow Up What has this 10 year follow up…
Biomarkers: Breast Cancer – Daniel Rotroff SABCS 2022 GENIE Trial What will help identify (biomarkers) genetics and inflammatory markers…
iFrame is not supported! Everolimus: Julie Gralow SABCS 2022 SWOG S1207 in HER2- Breast Cancer What is Everolimus and…
Everolimus: Julie Gralow SABCS 2022 SWOG S1207 in HER2- Breast Cancer What is Everolimus and how can it help…
RxPONDER trial (SWOG S1007) at SABCS 2022 presented by Yara Abdou, MD from the University of North CarolinaGS1-01 Race and…
iFrame is not supported! SV-BR-1-GM: Turning Cells into Antigen-presenting Cells Dr. Williams SABCS 2022 How does SV-BR-1-GM help turn…
SV-BR-1-GM: Turning Cells into Antigen-presenting Cells Dr. Williams SABCS 2022 How does SV-BR-1-GM help turn cells into antigen-presenting cells?…
iFrame is not supported! Omentum Based Reconstruction: For Pts with BMI < 25 kg/m Dr. Wapnir SABCS 2022 Will…
Omentum Based Reconstruction: For Pts with BMI < 25 kg/m Dr. Wapnir SABCS 2022 Will this data analysis or…
iFrame is not supported! How will the decreases in circulating tumor associated cells help patients with metastatic breast cancer? The…
SV-BR-1-GM: Pooled Analysis Predicts PFS and OS Dr. Williams SABCS 2022 How will the decreases in circulating tumor associated…
LW-02 Cartridge: Immunicom Therapy Amir Jafri CEO and Founder What is the LW-02 Cartridge Therapy? Immunicom was actually formed…
iFrame is not supported! SV-BR-1-GM: Whole Cell Therapeutic Vaccine Dr. Williams SABCS 2022 What is SV-BR-1-GM Whole Cell Therapeutic…
SV-BR-1-GM: Whole Cell Therapeutic Vaccine Dr. Williams SABCS 2022 What is SV-BR-1-GM Whole Cell Therapeutic Vaccine and how can…
iFrame is not supported! Tamoxifen: TAM-01 Long Term Follow-up with Andrea De Censi SABCS 2022 What is TAM-01 long term…
Tamoxifen: TAM-01 Long Term Follow-up with Andrea De Censi SABCS 2022 What is TAM-01 long term follow-up data? Tamoxifen is…
iFrame is not supported! Capivasertib: CAPItello-291 Results with Slides Nicholas Turner SABCS 2022 Presentation from the SABCS 2022 (San…
iFrame is not supported! Elacestrant PFS Increase ER+ HER2- Dr. Kaklamani, MD SABCS 2022 What is the EMERALD Trial…
Elacestrant PFS Increase ER+ HER2- Dr. Kaklamani, MD SABCS 2022 What is the EMERALD Trial In ER-positive, HER2-negative Metastatic…
iFrame is not supported! MUC4 Nude Mouse Model Trail in HER2+ Breast Cancer INmune Bio is focused on the innate…
iFrame is not supported! Camizestrant: Results of the Randomized Phase 2 SERENA-2 Trial (with slides) Thank you, Carlos. Thank…
iFrame is not supported! Breast Cancer Index: Predict Treatment SABCS 2022 Ruth O’Reagan What is the Breast Cancer Index? Ruth…
Capivasertib: CAPItello-291 Results with Slides Nicholas Turner SABCS 2022 Presentation from the SABCS 2022 (San Antonia Breast Cancer Symposium)…
Francois-Clement Bidard, MD, PhD of Institut Curiediscusses Circulating tumor cells enumeration and Health Related Quality of Life of patients treated…
MUC4 Nude Mouse Model Trail in HER2+ Breast Cancer INmune Bio is focused on the innate immune system in many…
Camizestrant: Results of the Randomized Phase 2 SERENA-2 Trial (with slides) Thank you, Carlos. Thank you, everyone, for the…
Yen-Shen Lu, MD of National Taiwan University discusses Ribociclib and the Primary results from the randomized Phase II RIGHT Choice…
RxPONDER trial (SWOG S1007) at SABCS 2022 presented by Yara Abdou, MD from the University of North CarolinaGS1-01 Race and…
Getting description
Breast Cancer Index: Predict Treatment SABCS 2022 Ruth O’Reagan What is the Breast Cancer Index? Ruth Regan, who is a…
HER2-Low: Anastrozole TRIO-US B-12 TALENT SABCS 2022Aditya Bardia, MD of Mass General discusses theGS2-03: TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan…
Trastuzumab emtansine versus Trastuzumab deruxtecan versus in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase…
Trastuzumab deruxtecan DESTINY-Breast02 results presented at SABCS 2022 with Ian E. Krop, MD, PhD Yale School of Medicine.GS2-01: Trastuzumab deruxtecan…
SABCS 2022 Day 2 Press Conference December 7, 2022. Ian E. Krop, MD, PhD from Yale University discusses Trastuzumab deruxtecan…
iFrame is not supported! Ribociclib: SABCS 2022 Phase II RIGHT Choice Trial in Breast Cancer What is the RIGHT…
Ribociclib: SABCS 2022 Phase II RIGHT Choice Trial in Breast Cancer What is the RIGHT Choice ribociclib clinical trial…
iFrame is not supported! Codagenix: What is CodaLytic? Who’s the target? Could Oncolytic Viruses Be Dangerous? CodaLytic is a…
Codagenix: What is CodaLytic? Who’s the target? Could Oncolytic Viruses Be Dangerous? CodaLytic is a novel Oncolytic virus that…
7-gene DCIS Assay [2022] Comparing Clinicopathologic Features 7-gene DCIS Assay: For several decades in clinical oncology, when it comes to…
7-gene DCIS Assay [2022] Comparing Clinicopathologic Features 7-gene DCIS Assay: For several decades in clinical oncology, when it comes to…
Breast Density Notification Rule: 2022 FDA: Dense Breasts The FDA Is Updating the Notification Rule For Women With Dense…
Male Breast Cancer: Clinical Signs [2022] What Are the Signs of Male Breast Cancer? And why do they go…
Male Breast Cancer: Clinical Signs [2022] iFrame is not supported! What Are the Signs of Male Breast Cancer? And why…
Breast Density Notification Rule: 2022 FDA: Dense Breasts iFrame is not supported! The FDA Is Updating the Notification Rule For…
Prioritizing Screening Mammogram: Help Early Diagnosis? Mammography (breast imaging) is one of the most commonly used preventive healthcare services (annual…
Dive into additional groundbreaking treatment approaches for triple-negative breast cancer (TNBC) in this tumor board, the second in a series…
Explore the latest groundbreaking treatment approaches for early-stage triple-negative breast cancer (TNBC) in this engaging tumor board! The multidisciplinary panel…
Can you make optimal treatment choices for challenging triple-negative breast cancer (TNBC) cases? Put your TNBC skills to the test…
Breast Cancer Screening [2022]: What Are We Missing? Are Women Avoiding Breast Cancer Screening? Because of COVID-19 and the subsequent…
Question and Answer Session Kay Yeung, MD, Ph.D. – ASCO [2022] Breast Cancer In-Depth Slides: MOASC https://oncologytube.com/v/41294 Kay Yeung, MD,…
ASCO [2022] Breast Cancer In-Depth Slides: MOASC Â Kay Yeung, MD, Ph.D. Delivers Her MOASC 2022 Breast Cancer Presentation Hello,…
ASCO 2022 Breast Cancer Overview: MOASC Spotlight  DESTINY-Breast04 Data from ASCO 2022 Annual Meeting I presented a lot of…
Olaparib Approved In Japan: Breast Cancer  Olaparib’s Study Design For BRCA1 or BRC2 Variants in Early Breast Cancer OlympiA…
T-DXd HER2-Positive Breast Cancer: DESTINY-Breast03 DESTINY-Breast03 Phase 3 clinical trial Study Design for HER2-Positive Breast Cancer This was a safety…
In this panel discussion and workshop, experts from the University of Chicago Medicine and the University of Illinois Cancer Center…
In this workshop, Dr. Nan Chen from the University of Chicago Medicine discusses the oncology, surgical, and radiation treatment experiences…
In this workshop, Dr. Nan Chen from the University of Chicago Medicine discusses screening and mammography rates among racial/ethnic groups.…
Listen as Amanda Kaczerski and Mahire Bonomo, Executive Director at the Center for Continuing Medical Education at The University of…
The University of Chicago Medicine and Ingalls Memorial Hospital are embarking on a quality improvement (QI) program to explore how…
Dr. John Stewart from the Louisiana State University School of Medicine discusses navigating complex treatment. The University of Chicago Medicine…
The University of Chicago Medicine and Ingalls Memorial Hospital are embarking on a quality improvement (QI) program to explore how…
Dr. Monical Peek from The University of Chicago discusses women’s fears and racial health inequities as part of a quality…
The University of Chicago Medicine and Ingalls Memorial Hospital are embarking on a quality improvement (QI) program to explore how…
Dr. Nan Chen from the University of Chicago Medicine shares a status update from ASCO on the quality improvement program…
Are you involved in treating patients with triple negative breast cancer (TNBC)? The emergence of TROP2-directed antibody drug conjugate (ADC)…
This study led us to the discovery of 53 gene signatures called IMPRINT and with the data we used to…
So, I’m talking about the AMEERA-6, which is a trial which is currently ongoing. So, we don’t yet have any…
So, I’m talking about the AMEERA-6, which is a trial which is currently ongoing. So, we don’t yet have any…
 Article: Transcript: Question – Please Tell Us About The AMEERA-6 Trial  So, I’m talking about AMEERA-6 which is…
Audio: So the I-SPY2 trial is a neoadjuvant phase 2 study that enrolls patients with any type of breast cancer…
Pathologic Complete Response: How may the I-SPY2 trial help HR positive HER2 negative Breast Cancer patients? Laura Huppert By Laura…
Transcript: So the I-SPY2Â trial is a neoadjuvant phase 2 study that enrolls patients with any type of breast cancer…
Audio: Enfortumab Vedotin was tested in a randomized phase 3 trial in patients with metastatic urothelial cancer who had previously…
Video: Enfortumab Vedotin was tested in a randomized phase 3 trial in patients with metastatic urothelial cancer who had previously…
Transcript – Where is the Elaine 2 Study and Just-in-time Model Right Now? – Article Question – Please Tell Us…
Audio: Open label phase 2 multi-center study looking at Lasofoxifene (LAS) in combination with a Abemaciclib (Abema) for treating postmenopausal…
Video: Open label phase 2 multi-center study looking at Lasofoxifene (LAS) in combination with a Abemaciclib (Abema) for treating postmenopausal…
Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology at…
DCISionRT: Assessing Breast Cancer Adjuvant Endocrine Therapy After BCS Chirag Shah MD By Chirag Shah, MD So this study was…
Cynthia X. Ma, MD, Professor, Department of Medicine, Oncology Division of Medial Oncology of Washington University School of Medicine. In…
Cynthia X. Ma, MD, Professor, Department of Medicine, Oncology Division of Medial Oncology of Washington University School of Medicine. In…
Angel Arnaout, MD, MSc, FRCSC, FACS, Regional Director of Breast Surgical Oncology, part of the Ottawa Breast Cancer Biomarker Research…
Angel Arnaout, MD, MSc, FRCSC, FACS, Regional Director of Breast Surgical Oncology, part of the Ottawa Breast Cancer Biomarker Research…
Erika Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator at Sarah Cannon Research Institute. In this…
Erika Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator at Sarah Cannon Research Institute. In this…
Douglas W. Blayney, MD, FASCO, Clinical researcher and breast oncologist, Professor of Medicine at Stanford University. In this audio, he…
Douglas W. Blayney, MD, FASCO, Clinical researcher and breast oncologist, Professor of Medicine at Stanford University. In this video, he…
Debra A. Patt, MD, Ph.D., MBA, FASCO, is a practicing oncologist and breast cancer specialist in Austin, Texas, and an…
Debra A. Patt, MD, Ph.D., MBA, FASCO, is a practicing oncologist and breast cancer specialist in Austin, Texas, and an…
Ian Krop, MD, Ph.D., Associate Cancer Center Director for Clinical Research; Yale Cancer Center. In this video, he speaks about…
Ian Krop, MD, Ph.D., Associate Cancer Center Director for Clinical Research; Yale Cancer Center. In this video, he speaks about…
Maria Soledad Sosa, Ph.D., Assistant Professor of Pharmacological Sciences, and Oncological Sciences, at The Tisch Cancer Institute at Mount Sinai.…
Maria Soledad Sosa, Ph.D., Assistant Professor of Pharmacological Sciences, and Oncological Sciences, at The Tisch Cancer Institute at Mount Sinai.…
Dennis J. Slamon, MD, Director of Clinical/Translational Research, University of California, Los Angeles Jonsson Comprehensive Cancer Center. In this video,…
Dennis J. Slamon, MD, Director of Clinical/Translational Research, University of California, Los Angeles Jonsson Comprehensive Cancer Center. In this video,…
Laura Alder, MD, Hematology-Oncology Fellow at Duke University Health System. In this video, she speaks about the AACR 2022 Abstract…
Laura Alder, MD, Hematology-Oncology Fellow at Duke University Health System. In this video, she speaks about the AACR 2022 Abstract…
Michael J. Donovan, MD, Ph.D., Research Professor of Pathology, Molecular, and Cell-Based Medicine at Icahn School of Medicine at Mount…
Michael J. Donovan, MD, Ph.D., Research Professor of Pathology, Molecular, and Cell-Based Medicine at Icahn School of Medicine at Mount…
Javier Cortés, MD, Ph.D., Founder, and director of the International Breast Cancer Center (IBCC), in Madrid, Spain. Dr. Javier Cortés…
Javier Cortés, MD, Ph.D., Founder, and director of the International Breast Cancer Center (IBCC), in Madrid, Spain. Dr. Javier Cortés…
Yuan Yuan, Ph.D., medical oncologist, City of Hope, and Colt Egelston, Ph.D., assistant research professor at the Beckman Research Institute…
Yuan Yuan, Ph.D., medical oncologist, City of Hope, and Colt Egelston, Ph.D., assistant research professor at the Beckman Research Institute…
Mark LaBarge, Ph.D., professor, Department of Population Sciences, City of Hope. In this video, he speaks about the AACR 2022…
Mark LaBarge, Ph.D., professor, Department of Population Sciences, City of Hope. In this video, he speaks about the AACR 2022…
Mariya Rozenblit, MD, Instructor of Medicine (Medical Oncology) and cares for patients with a clinical focus on breast cancer from…
Mariya Rozenblit, MD, Instructor of Medicine (Medical Oncology) and cares for patients with a clinical focus on breast cancer from…